



NEWS RELEASE

Biosensors Celebrates a Year of Achievement at TCT with an Expanded Product Portfolio

25 October 2013 – Biosensors International is celebrating a year of significant achievement with an expanded product portfolio, offering physicians a broader range of treatment options to improve patient outcomes.

Since TCT 2012, the company has revitalized its core offering with the launch of BioMatrix NeoFlex™, a DES with exceptional performance in complex lesions and challenging anatomies; expanded its range of dedicated bifurcation stents with Axxess™ 4.0x9, designed to treat larger, shorter and wider-angulated bifurcations; complemented its stent portfolio by introducing BioStream™ and BioPath™, drug-eluting balloon dilation catheters for the treatment of coronary and peripheral artery disease respectively; and re-established its leadership in coronary stent technology with the introduction of BioFreedom™, the world's first polymer-free stent coated with Biolimus A9™.

In May 2013 Biosensors took a significant step towards revolutionizing patient care with the acquisition of functional imaging company Spectrum Dynamics, whose expertise will help cath labs determine which patients require a stent without the need for diagnostic angiography. Spectrum Dynamics's technology is faster than conventional functional imaging, requires less contrast medium to be injected, and can deliver up to 10 times the sensitivity and twice the spatial resolution.

"We have come further than we could possibly have imagined since last year's TCT", commented Jeffrey B. Jump, President of Biosensors' Cardiovascular Division. "Over the last twelve months we have revamped the leading biodegradable polymer DES, increased the applications for our specialist bifurcation stent, offered cath labs a wider choice of treatment options with a range of drug-eluting balloons and acquired technology with the potential to fundamentally change the way that interventional cardiology is practiced: so who knows what we can achieve over the next twelve months!"

Visitors to TCT can find full details on Biosensors' expanded portfolio at Booth 1607 in Hall B.

###

Media Contacts:

Biosensors Corporate Communications
Richard Kenyon
Biosensors International Group
+44 7831 569940
r.kenyon@biosensors.com

Biosensors Investor Relations
Wong Teck Yenn
Biosensors International Group
+65 6213 5708
ty.wong@biosensors.com

About Biosensors International Group, Ltd

Biosensors International develops, manufactures and markets innovative medical devices for interventional cardiology and critical care procedures. We aim to improve patients' lives through pioneering medical technology that pushes forward the boundaries of innovation.

With the BioMatrix™ family of drug-eluting stents and the Axxess™ self-expanding bifurcation stent, we are one of the leaders in the global coronary stent market. These stents incorporate Biolimus A9™ (BA9™), an anti-restenotic drug developed and patented by Biosensors specifically for use with stents, together with a unique abluminal biodegradable polymer coating, which fully degrades into carbon dioxide and water after six to nine months as it releases BA9. The BioMatrix family features workhorse stent platforms for a broad range of lesions, and Axxess employs a self-expanding stent platform specifically designed for treating bifurcation lesions.

The BioFreedom™ drug-coated stent, which has now received CE Mark approval, re-establishes our technology leadership in the field of coronary stents. BioFreedom is the world's first polymer-free stent with BA9. Chroma™, a cobalt chromium bare-metal stent featuring an innovative platform design, offers exceptional deliverability without any compromise on radial strength or recoil.

The recent launch of our drug-eluting balloon range complements our stent portfolio and offers interventional cardiologists a broader range of treatment options.

For more information, please visit www.biosensors.com.